Streetbeat News

Partnerships

ASND

Specialised Therapeutics Asia has signed an exclusive agreement with Ascendis Pharma to distribute and commercialize three endocrinology therapies in Australia and select South-East Asia countries. The therapies include SKYTROFA for paediatric growth hormone deficiency, YORVIPA for hypoparathyroidism, and TransCon CNP for achondroplasia. The agreement covers Australia, New Zealand, Singapore, Malaysia, Brunei, Thailand, and Vietnam. Two of the products are already internationally approved.

Portfolio Pulse from Charles Gross

January 07, 2024 | 7:34 pm

AKYA

Akoya Biosciences, Inc. (NASDAQ:AKYA) has announced the deployment of the MaxFuse algorithm, co-developed with Dr. Garry Nolan's lab at Stanford University, for multiomic integration of spatial and single-cell data on the Enable Medicine platform. Dr. Nolan is a co-founder and board member of Akoya Biosciences, which specializes in spatial biology and collaborates with Enable Medicine, a provider of AI-powered biological insights.

Portfolio Pulse from Charles Gross

January 07, 2024 | 4:06 pm

AKYA

TMO

Akoya Biosciences, Inc. (AKYA) has entered into a license and distribution agreement with Thermo Fisher Scientific, Inc. (TMO) to market a spatial multiomics workflow. This collaboration combines Akoya's PhenoImager systems and PhenoCode reagents with Thermo Fisher's ViewRNA In Situ Hybridization Assays. The partnership aims to provide a comprehensive suite of multiomic solutions to enhance the understanding of tumor progression and biomarker development.

Portfolio Pulse from Charles Gross

January 07, 2024 | 4:05 pm

HEMP

During Dry January, the cannabis industry is offering alternatives to alcohol with new products. Cheech Marin and Tommy Chong have partnered with NorthEast Extracts LLC to launch their cannabis products in New York. BioWellnessX has introduced a premium THCa flower wholesale line. WhistlePig Whiskey has released a non-alcoholic, terpene-infused cocktail with proceeds benefiting Turning Tables. Illicit Gardens and Monopoly Melts have collaborated on Hash Holes, a series of craft pre-rolls. Hemp, Inc. is capitalizing on the demand for hemp-derived products, while Kiva Confections' Camino gummies offer a cost-effective and healthy alternative to cocktails.

Portfolio Pulse from Joana Scopel

January 07, 2024 | 3:53 pm

LCID

NIO

RIVN

TSLA

VWYAG

Argus analyst Bill Selesky maintains a bullish stance on Tesla, Inc. (NASDAQ:TSLA), predicting a 33% stock rally as he expects the company's growth to reaccelerate in 2024. Selesky cites Tesla's artificial intelligence in manufacturing and factory utilization as a significant competitive advantage. He also notes Tesla's current leadership in the EV market and potential for increased market share. Despite challenges faced by competitors like Ford (NYSE:F), General Motors (NYSE:GM), Toyota (NYSE:TM), Volkswagen (OTC:VWYAG), Nio (NYSE:NIO), Lucid Motors (NASDAQ:LCID), and Rivian (NASDAQ:RIVN), Tesla is poised for growth. Argus has set a $316 price target for Tesla stock.

Portfolio Pulse from Shanthi Rexaline

January 07, 2024 | 2:07 pm

AAPL

GOOG

GOOGL

MSFT

Apple Inc. (AAPL) had a significant week with opposition to UK surveillance laws, legal challenges, rumors of an early Vision Pro launch, and no new iPad in 2023. Apple, along with Alphabet Inc. (GOOG, GOOGL) and Microsoft Corp. (MSFT), opposed the UK's proposed surveillance laws through techUK. Apple's services business faces legal scrutiny, potentially affecting its revenue. The Vision Pro headset is rumored to launch in January, and new iPhones may have advanced cameras. The absence of a new iPad model breaks a 12-year tradition.

Portfolio Pulse from Benzinga Neuro

January 07, 2024 | 11:01 am

PLTR

Palantir Technologies Inc. (NYSE:PLTR) is under investigation by the UK's National Health Service (NHS) for potentially breaching contract terms related to marketing activities. The breach concerns an influencer marketing campaign by Topham Guerin, which was not approved by NHS England as required by the contract. Palantir, which won a £330 million contract with Accenture Plc to build the NHS Federated Data Platform, has stopped working with Topham Guerin and described the campaign as an 'exploratory project.' The Good Law Project has raised concerns about Palantir's handling of private medical data and transparency of the data processing platform.

Portfolio Pulse from Nabaparna Bhattacharya

January 06, 2024 | 8:42 pm

CMCSA

NTDOY

SONY

Following the success of 'The Super Mario Bros. Movie,' which grossed over $1 billion, Nintendo Co (OTC:NTDOY) is hinted to be exploring more film projects. Shigeru Miyamoto, Mario's creator, is considering unique opportunities for Nintendo in movies and amusement parks. Comcast Corporation (NASDAQ:CMCSA), through Universal Pictures, distributed the Mario movie. A 'The Legend of Zelda' live-action film, a collaboration between Nintendo and Sony Group Corp (NYSE:SONY), has also been announced. The success of the Mario movie and potential sequels or spinoffs could positively impact Nintendo's stock, which has seen a 21% increase over the last year.

Portfolio Pulse from Chris Katje

January 06, 2024 | 1:19 pm

PRME

Prime Medicine, Inc. (NASDAQ:PRME) and Myeloid Therapeutics, Inc. have announced the resolution of all outstanding disputes, ending pending arbitrations. Both companies view the settlement as positive, allowing them to focus on developing therapies for patients. The CEOs of both companies expressed satisfaction with the outcome and a commitment to advancing their respective scientific and commercial goals.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 10:04 pm

AAPL

AMZN

ASTS

TMUS

TSLA

VOD

SpaceX, led by Elon Musk, has launched its first set of direct-to-cell Starlink satellites, partnering with T-Mobile US to potentially enter the telecommunications market. The technology aims to provide mobile phone connectivity anywhere on Earth, especially in areas with limited connectivity. SpaceX plans to offer text messaging this year and voice and data services by 2025, pending further FCC approvals. The move could increase SpaceX's customer base and compete with similar initiatives by Apple, Amazon's Project Kuiper, and AST SpaceMobile.

Portfolio Pulse from Chris Katje

January 05, 2024 | 10:01 pm